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Abstract
Small Cell Lung Cancer (SCLC) is a specific subtype of lung cancer presenting as highly metastatic disease with extremely
poor prognosis. Despite responding initially well to chemo- or radiotherapy, SCLC almost invariably relapses and develops
resistance to chemotherapy. This is suspected to be related to tumor cell subpopulations with different characteristics
resembling stem cells. Epithelial-Mesenchymal Transition (EMT) is known to play a key role in metastatic processes and in
developing drug resistance. This is also true for NSCLC, but there is very little information on EMT processes in SCLC so far.
SCLC, in contrast to NSCLC cell lines, grow mainly in floating cell clusters and a minor part as adherent cells. We compared
these morphologically different subpopulations of SCLC cell lines for EMT and epigenetic features, detecting significant
differences in the adherent subpopulations with high levels of mesenchymal markers such as Vimentin and Fibronectin and
very low levels of epithelial markers like E-cadherin and Zona Occludens 1. In addition, expression of EMT-related
transcription factors such as Snail/Snai1, Slug/Snai2, and Zeb1, DNA methylation patterns of the EMT hallmark genes,
functional responses like migration, invasion, matrix metalloproteases secretion, and resistance to chemotherapeutic drug
treatment all differed significantly between the sublines. This phenotypic variability might reflect tumor cell heterogeneity
and EMT during metastasis in vivo, accompanied by the development of refractory disease in relapse. We propose that
epigenetic regulation plays a key role during phenotypical and functional changes in tumor cells and might therefore
provide new treatment options for SCLC patients.
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Introduction
Small cell lung cancer (SCLC) is a highly malignant and
aggressive pulmonary neoplasm accounting for approximately 10–
15% of all lung cancers reported. About 30,000 cases are
diagnosed per year in the United States [1,2]. As a separate
lung-cancer subgroup distinct from Non Small Cell Lung Cancer
(NSCLC, including squamous cell carcinoma, large cell carcino-
ma, and adenocarcinoma), SCLC is characterized by very early
metastasis and poor prognosis. Most patients present with nodal
metastases, and two-thirds already have distant metastases at the
time of diagnosis [3]. Despite responding initially well to radio-
and chemotherapy, the vast majority relapses with a 1-year
survival rate for SCLC of only 40%, and 5-year survival under 5%
[4]. Whereas NSCLC treatment has progressed in recent years,
SCLC treatment remains unsatisfactory [5]. We have witnessed no
significant advances in its treatment over the last 30 years since the
standard regimen of Etoposide in combination with Cisplatin or
Carboplatin was established during the mid-1980s [6]; surgical
resection is the exception and might only benefit a minority of
careful selected patients [7]. There is obviously an urgent need for
new approaches for understanding and treating this specific lung
cancer subtype.
SCLC assumes a wide range of morphological appearances
histopathologically, with tumor cells usually smaller than the size
of 3 resting lymphocytes. However, there are samples containing
cells reaching as large as 7 lymphocytes, demonstrating their
morphological variability [8] within the tumor tissue. Typical
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cytological features are finely granulated chromatin, lack of
prominent nucleoli and cell borders, and the expression of
neuroendocrine markers [8]. Since 2004, SCLC’s WHO classifi-
cation describes two subtypes: pure SCLC with less than 10%
large cells, and combined SCLC with over 10% non–small-cell
components [9]. Tumors with a high amount of non–small-cell
components are described as being more therapy-resistant than
pure SCLC [10]. It has also been postulated that SCLC tumors
acquire chemo- and radioresistance during treatment, evolving
into combined SCLC [11].
To metastasize, cells need to change their phenotype. Individual
cells or small groups of cells acquire the ability to migrate and
invade through the surrounding tissue’s basal membrane. During
this process, tumor cells disband cell-cell connections, losing their
basal-apical polarity, accompanied by morphologic changes
revealing a spindle shape, after which microvilli, filopodia and
microtentacles become pronounced instead. Moreover, proteases
like Matrix Metalloproteinases (MMPs) become upregulated,
facilitating degradation of the extracellular matrix. These process-
es are also known as the epithelial–mesenchymal transition (EMT)
and have been described in a variety of cancer types [12–15].
However, there is almost no information on EMT processes in
SCLC so far [16]. There is evidence that EMT is critical to both
metastasis and in conjunction with chemo- and radioresistance
[17]. EMT is a multistage process involving pronounced cellular
plasticity and numerous distinct genetic and epigenetic alterations
[18]. Transcription factors such as Snail/Snai1, Slug/Snai2, Zeb1,
FSP and others cause the up- and downregulation of several genes.
E-cadherin has been described as a central factor in the transition
between the epithelial and mesenchymal phenotype. Zeb1 and
Snail/Snai1 bind to E-cadherin promoter and repress the
transcription of cell adhesion molecules [19]. Whereas E-cadherin
and Zona Occludens 1 are typically downregulated during EMT,
mesenchymal genes such as Vimentin, Fibronectin, and MMPs
are upregulated. Epigenetic changes such as DNA methylation,
histone modifications and microRNAs are known to be involved in
EMT-related gene regulation [15] and therefore might also be
responsible for changes in cell phenotype in order to enable
spreading and adapting to new micro-environments.
In this study we analyzed different cell subpopulations in SCLC
cells lines, especially in NCI-H69 cells, for differences in EMT key
genes and functional characteristics. We compared floating-cell
aggregates (NCI-H69) with adherently-growing variant subpopu-
lations (NCI-H69V). NCI-H69V was selected from the parental
cell line NCI-H69 and is a variant due to low levels of
neuroendocrine markers [20]. Comparing the sublines of NCI-
H69 clearly reveals a different expression pattern for EMT
markers and DNA methylation, which is in turn associated with
functional consequences such as the capacity for invasion,
migration, MMP secretion and activation, cell proliferation, and
chemoresistance. In summary, this study postulates that there is a
proportion of mesenchymal cells within SCLC cell lines which
might reflect the in-vivo situation in SCLC with tumors containing
heterogeneous tumor cell subpopulations with more or less
epithelial and/or mesenchymal characteristics which might be
associated with the functional responses during the metastasis
processes.
Materials and Methods
Cell culture and reagents
Human SCLC cell lines NCI-H69, NCI-H82 and NCI-N592
were obtained from the American Type Culture Collection
(ATCC - Manassas, VA, USA). NCI-H69 and NCI-N592 were
verified by LGC Standards Cell Line Authentication. NCI-H69V
were kindly provided by the BIOSS Toolbox (Freiburg, Germany).
In addition, NCI-H69 and NCI-H69V cells were compared by
SNP array (data not shown), which proved same cellular origin. All
cell lines were maintained in RPMI (Gibco-BRL, Grand Island,
NY, USA) supplemented with 10% Fetal Calf Serum (FCS) and
1% penicillin/streptomycin (Gibco-BRL, Grand Island, NY, USA)
in a humidified atmosphere (5% CO2) at 37uC. In order to select
for adherent subpopulations, the adherent cells within NCI-H69,
NCI-H82 and NCI-N592 were kept in culture, whereas floating
cells were disposed over multiple passages.
Growth rates and population doubling time
Growth rates of NCI-H69 and NCI-H69V were determined
seeding 3*106 cells (in triplicates) into tissue culture flasks. Cells
were counted on day 2, 4 and 6 using a hemocytometer. To
calculate population doubling time (PDT), the formula
PDT = h*ln(2)/ln(c2/c1) was used according to ATCC guidelines.
Immunofluorescence staining of Vimentin, E-cadherin,
Zona Occludens and Ki-67
Cells were fixed in 2% PFA, permeabilized with 0.5% TritonX-
100 at 4u for 10 min, and blocked with PBS containing 5.0% (v/v)
normal goat serum and 0.3% (v/v) Triton X-100. Immunofluo-
rescence staining was performed with mouse mAb Ki-67 (Dako,
Hamburg, Germany), Vimentin XP Rabbit mAb, E-cadherin
rabbit mAb and Zona Occludens mAb (Cell Signaling Technol-
ogies, MA, USA), and appropriate secondary antibodies (goat-
anti-mouse IgG-Alexa488 and goat-anti-rabbit IgG-Alexa467,
Invitrogen, Karlsruhe, Germany). The slides were then mounted
with Prolong Gold Antifade Reagent with DAPI (Invitrogen Life
Technologies, Carlsbad, CA, USA).
Reverse transcription PCR analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions,
followed by DNA digestion with DNase I (Applied Biosystems,
Warrington, Cheshire, UK). For cDNA synthesis 1 mg of total
RNA was transcribed using the iScript kit (Bio-Rad, Hercules, CA,
USA). The cDNA was amplified using Taq polymerase (Qiagen,
Hilden, Germany) using following PCR program for all primers:
94uC for 5 min followed by 28 cycles of 94uC 30 sec, 55uC 30 sec
and 72uC for 30 sec and last round of amplification at 72uC for
5 min. PCR products were analyzed on a 1.0% agarose gel,
visualized, and photographed under UV light. For quantification,
PCR bands were analyzed by ImageJ 1.42q. For primer sequences
see Table 1.
Preparation of cell extracts and western blot analysis
Cells were washed with ice-cold PBS, and lysed using
Qproteome Mammalian Protein Prep Kit (Qiagen, Hilden,
Germany) or by lysis buffer containing 20 mM Tris/HCl
pH 8.0, 150 mM KCl, 1 mM EDTA, 0.2 mM Na3VO4, 1%
Triton X-100, 0.5 mM PMSF with protein inhibitor cocktail
(complete, Roche Applied Science, Basel, Switzerland). Equal
amounts of protein samples were denatured at 95uC for 5 minutes,
separated by 10% SDS-PAGE and transferred onto PDVF
membranes. Membranes were then blocked with 5% non-fat dry
milk in PBS/0.1% Tween-20 and incubated overnight with the
following antibodies: ZO-1 mAB, Vimentin XP rabbit mAb, E-
cadherin rabbit mAb, Snail rabbit mAb, Slug rabbit mAb, TCF8/
ZEB1 Rabbit mAb, b-Catenin rabbit mAb Anti-rabbit IgG,
GAPDH rabbit mAb, HRP-linked Antibody (Epithelial-Mesen-
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chymal Transition (EMT) Antibody Sampler Kit #9782 from Cell
Signaling Technologies, MA, USA) and L-Dopa (#8786 Cell
Signaling Technologies, MA, USA), Neuron-specific enolase
(NSE) (#9536 Cell Signaling Technologies, MA, USA). Finally,
immunoreactive bands were visualized using horseradish perox-
idase-conjugated secondary antibodies and the enhanced chemi-
luminescence system (Amersham Biosciences, Freiburg, Ger-
many).
Pyrosequencing
Genomic DNA was extracted using DNeasy Blood & Tissue Kit
(Qiagen, Hilden, Germany) and quantified using a NanoDrop
1000 Spectrophotometer (peqlab, Erlangen, Germany). DNA was
bisulfite-treated using the EZ DNA Methylation-Gold Kit (Zymo
Research, CA, USA) according to the manufacturer’s instructions
and stored in aliquots at 220uC until use. PCR Primers were
designed using Pyrosequencing Assay Design Software (Qiagen,
Hilden,Germany) (Tab.2). A universal tag was placed at the 59end
of the sequence-specific reverse primer for CDH1 and a
corresponding universal biotinylated primer containing a 59 biotin
label was added to these PCR reactions. The 59end of the
sequence-specific reverse primer used for VIM amplicon 1 and
amplicon 2 was biotin labeled. The amplicon (spanning 261 to +
18 with respect to the TSS) of CDH1 included seven CpG sites. In
case of Vimentin, the amplicon was divided into two parts,
separated by a 73-bp gap. The first amplicon of Vimentin between
nt +608 to +703 with respect to the TSS contained twelve and the
second amplicon (spanning +468 to +537 with respect to the TSS)
eight CpG sites, respectively. Each 25 ml PCR reaction contained
1.5 mM MgCl2, 0.4 mM dNTP, 0.03 U/ml Hot start Taq DNA
polymerase (Invitrogen, CA, USA), 0.16 mM forward and reverse
primer and 1 ml of bisulfite treated DNA. For CDH1 0.16 mM
forward primer and 0.03 ml tailed reverse primer and 0.14 mM
universal biotinylated primer was used. Cycling conditions were as
follows: 95uC for 5 min for initial denaturation; 50 cycles of
denaturation at 94uC for 30 seconds, varying annealing temper-
ature for 30 s and extension at 72uC for 30 s. PCR products were
visualized on 2% agarose gels. Every pyrosequencing reaction was
obtained with 8–10 ml of each biotinylated PCR product and the
Pyromark Gold Kit according to the manufacturer’s instructions
on a PyroMark Q96 MD pyrosequencer (Qiagen, Hilden,
Germany). In brief, biotinylated single strand DNA was immobi-
lized on streptavidin-coated Sepharose High Performance beads
(GE healthcare, UK) and separated by denaturation with 0.2 N
NaOH. After annealing of the sequencing primer (0,25 mM/
reaction) to the biotinylated single-strand DNA, the mix was
subjected to sequencing. Pyrograms were analyzed using the Pyro
Q-CpG software to determine the methylation level of methylated
and unmethylated cytosines at each CpG site in the amplicon.
Each pyrosequencing analysis was independently performed at
least three times. Student’s unpaired t tests were conducted to test
statistical differences in the mean methylation level of the analyzed
amplicons. Cultured lung fibroblasts isolated from three patients
without fibrotic diseases served as normal control. The primer
pairs used for PCR are listed in Table 2.
Live-cell proteolysis assay
LabTek 4-well chamber slides were coated with phenol-red free
basement membrane matrix, containing 30 ng/ml DQ-Collagen
IV (Invitrogen Life Technologies, Carlsbad, CA, USA). After
12 min solidification, 36104 cells in phenol-red free RPMI with
1% FCS were plated on top of the coated basement membrane
matrix. After 48 h incubation, cells were fixed with 2% PFA,
stained with Hoechst and mounted. Degradation products of the
DQ-substrate (green fluorescence) were analyzed on an automated
microscope (scan‘R - Olympus) using a 20x, N.A. 0.75 UPLSAPO
objective with Hoechst emission measured at 440–475 nm and
DQ-Collagen at 520–550 nm. The mean intensity of DQ-
substrate degradation was calculated using the scan‘R Analysis
Software (v. 1.2.0.6) and normalized to the number of cell nuclei.
Matrix metalloproteinase antibody array
Matrix metalloproteinases in cell-conditioned media were
analyzed with the Human MMP Array 1 (RayBiotech, Norcross,
GA, USA). Cells were washed with PBS and incubated with FCS-
free and phenol-red free RPMI 1640 overnight. After centrifuga-
tion, cell conditioned medium was applied to the pre-blocked
membranes, incubated at 4uC overnight and processed according
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to the manufacturer’s instructions. Antibody arrays were quanti-
fied with ImageJ software v. 1.42q.
Gelatine Zymography
MMP-2 and MMP-9 activities were assessed by gelatin
zymography. Cells were washed with PBS and incubated with
FCS-free and phenol-red free RPMI 1640 overnight. Cell
conditioned media were concentrated using Amicon Ultracel
10 k columns. After determining protein concentrations by
Bradford assay, equal amounts of protein and 2 ml MMP-2
Zymography Control (ProteaImmun, Berlin, Germany) were
electrophoresed in 7% SDS-polyacrylamide gels, containing
1 mg/ml gelatin (Merck, Darmstadt, Germany). Gels were washed
in 2.5% Triton X-100 solution for 1 hour, then incubated
overnight in incubation buffer (0,05 M Tris/HCl pH 7,5, 0,2 M
NaCl and 0,005 M CaCl2) at 37 uC. Gels were fixed in 12% TCA
for 1 hour and stained in Coomassie brilliant blue-R250 staining
solution for 1 hour, followed by destaining. For loading controls,
samples were loaded onto SDS-PAGE and stained by Coomassie
brilliant blue-R250 staining.
Drug Resistance
To test chemosensitivity, 36104 NCI-H69 or NCI-H69V cells
were seeded in 6 well plates for 12 h and were then treated with
200 mM Etoposide (Sigma-Aldrich, Munich, Germany) for 48 h as
described before [21]. Afterwards, cell viability was tested using
propidium iodide (PI) (Sigma-Aldrich, Munich, Germany) and
3,39-dihexyloxacarbocyanine iodide (DIOC6) (Sigma-Aldrich,
Munich, Germany). Cells were incubated in RPMI 1640
containing 0.5% BSA, 10 nM DIOC 6 and 2 mg/ml PI at
37uC for 20 min and analyzed by flow cytometry on a
FACSCalibur (Becton Dickinson, Mountain View, CA, USA).
Flow cytometry data were analyzed using FlowJo software v.7.6.3
(Tree Star Inc., San Carlos, CA, USA).
Transwell migration
Migration of SCLC cells was evaluated using 24-well micro-
chemotaxis plates (Costar, New York, USA), in which 16106 cells
in 100 mL RPMI 1640 without FCS after starvation for 12 hours
were put into the upper chamber and the lower chamber
contained RPMI with 10% FCS. After 24 h of incubation at
37uC in 5% CO2, cells were counted according to the
manufacturer’s instructions. Invaded cells at the bottom of the
insert membrane were dissociated with trypsin and counted using
a hemocytometer. Migration Index was calculated as the number
of migrated cells divided by number of migrated cells in the
untreated group. Each experiment was done in triplicate. Data
represent mean +/2 SD from three independent experiments.
Invasion assays
For invasion assays the QCMTM 24-Well Cell Invasion Assay
(ECM 550; Chemicon International, Temecula, CA, USA) with
an 8 mM pore size polycarbonate membrane and a layer of
ECMatrix-like material was used. Assays were done according to
the manufacturer’s instructions, by which 66105 cells were starved
for 12 h, seeded into the upper chamber, and incubated for 48 h
at 37uC and 5% CO2. The lower chamber contained RPMI with
10% FCS. After 48 h cells in the upper chamber were removed
using cotton swabs, invaded cells at the bottom of the insert
membrane were dissociated with trypsin and counted using a
hemocytometer. Experiments were performed in triplicate.
Statistical analysis
Statistical significance between controls and individual condi-
tions was assessed by GraphPad Prism 5 Software using the t-test.
* represents a P value from 0.01 to 0.05, ** represents a P value
from 0.01 to 0.001 and *** represents a P value less than 0.001. A
p value of ,0.05 was considered to be statistic significant.
Results
The key EMT markers Vimentin and E-cadherin are
differentially expressed
SCLC cell lines such as NCI-H69 typically grow as tightly-
packed floating aggregates. However, a consistent proportion (5–
10%) of the total observable cell number grows adherently. For the
cell line NCI-H69 an adherent subline has been established named
NCI-H69V [20]. Immunofluorescent staining differed consider-
ably when comparing NCI-H69 and its subline NCI-H69V for the
key markers of epithelial and mesenchymal cell phenotypes E-
cadherin and Vimentin: NCI-H69 were positive for E-cadherin
(Figure 1a) and Zona Occludens (Figure 1b) but showed no
Vimentin expression (Figure 1c), whereas the adherent NCI-H69V
was negative for E-cadherin (Figure 1d) but strongly positive for
Table 2. Primers used for pyrosequencing.
Tm [6C] amplicon [hg19]
CDH1 forward primer(59- 39) GGTTGTGGTAGGTAGGTGAATT 56uC chr16:68,771,134–
68,771,212
reverse primer (59-39) GTGCCAGGCTCAGGCAAACTAACTTCCCCAAACTCACAAATACTT 56uC
universal biotinylated primer (59-39) BTN-ATCTGTGCCAGGCTCAGGC 56uC
sequencing primer (59- 39) GGTAGGTGAATTTTTAGTTAA
VIM amp1 forward primer(59- 39) GGGTTTATTTTGGGGTGTTGAA 60uC chr10:17,270,868–
17,270,957
reverse primer (59-39) BTN-ACTTCAAATCTAAAAAATTCCTTACTCT 60uC
sequencing primer (59- 39) GTTTGGGATTGAATTAGAG
VIM amp2 forward primer(59- 39) GGGAAGAGGAAAGAGTAAGGAATTT 56uC chr10:17,270,725–
17,270,794
reverse primer (59-39) BTN-ACAACCCCCCTTTCCAAAC 56uC
sequencing primer (59- 39) AATAAAGAGAGTTTGAGATTGG
doi:10.1371/journal.pone.0100249.t002
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Vimentin (Figure 1f). Majority of NCI-H69V cells were negative
for Zona Occludens (Figure 1e); however some single cells showed
slight remaining Zona Occludens expression (Figure 1e, asterisk).
Expression of E-cadherin and Vimentin, as hallmark genes of
EMT, distinguishes between the different subpopulations within
the cell line, demonstrating a majority of epithelial-like cells and
fewer adherently-growing cells with a mesenchymal-like pheno-
type.
Different cell morphology within SCLC cell lines
We investigated the cell morphology of subpopulations (floating
vs. adherent) in SCLC cell lines. For this purpose the adherent
subpopulation was increased by selection until the cells grew as a
completely adherent monolayer (Figures 2b, e, g). The cell lines
showed differences in spontaneous adherence: NCI-N592 attached
more frequently and quicker than NCI-H69 (NCI-H69: Figures 2a,
b/NCI-N592: Figures 2d, e). An adherent subline has been
established for NCI-H69, namely NCI-H69V (Figure 2c) [20].
The adherent cell line we selected ourselves revealed similar
morphology (Figures 2b, c). Growth rates and doubling times of
NCI-H69 and NCI-H69V were comparable with 28 h (66,02) for
NCI-H69 and 30 h (67,34) for NCI-H69V (Figure S1).
There are impressive morphological differences between
adherent and floating cells in all investigated SCLC cell lines:
whereas cells in floating clusters appear small and round, with
small nuclei, attached cells are larger, spread out, and have a large
cytoplasm-to-nucleus ratio. In particular, NCI-H69V cells have a
spindle shape with long pseudopodia and fibers, fine granular
chromatin and a lack of prominent nucleoli. In addition, adherent
cells do not grow via tight cell-cell contacts until they are highly
confluent.
Expression of EMT-related genes and DNA methylation
changes in Vimentin and E-cadherin during EMT
mRNA expression of typical EMT gene products were
compared between the different SCLC cell lines and its selected
adherent sublines by RT-PCR (Figure 3a). The epithelial marker
gene E-cadherin was highly expressed in floating NCI-H69. In
contrast, E-cadherin expression was low in adherent NCI-H69V.
Vimentin was absent in the floating NCI-H69 cells, whereas it was
strongly expressed in adherently growing NCI-H69adh and NCI-
H69V (Figure 3a). These differences in mRNA expression were
also detected in NCI-H82 and NCI-N592 sublines, with the
adherent cells demonstrating a more mesenchymal-like pattern.
However, the conversion was not as clear as that in NCI-H69/
NCI-H69V (Figure 3a).
Taken together, the EMT-related transcription factors Zeb1,
Snail/Snai1, Slug/Snai2 and FSP were expressed variably in the
different cell lines (Figure 3a). We noted the strongest differences
in NCI-H69V in comparison to NCI-H69 and therefore focused
on those cells in the following experiments.
This conversion from epithelial NCI-H69 cells into a mesen-
chymal phenotype (NCI-H69V) was demonstrated even more
obviously on the protein level (Figure 3b): we detected significant
downregulation of the epithelial markers E-cadherin and Zona
occludens 1 in NCI-H69V accompanied by upregulation of EMT
inductors and effectors such as ZEB1, Snail/Snai1, Slug/Snai2
and Vimentin. Although the mRNA expression of NCI-N592 only
tended toward a mesenchymal phenotype (Figure 3a), protein
expression clearly revealed a mesenchymal pattern (Figure 3b).
Interestingly, the neuroendocrine markers NSE and L-Dopa
were expressed in the parental cell line NCI-H69, but were not
detectable in its adherent subline (Figure 3c).
Figure 1. Immunofluorescence staining for EMT markers. Suspension cells (NCI-H69) are strongly positive for E-cadherin (red) (a) and Zona
Occludens (red) (b), whereas adherent NCI-H69V cells are negative for E-cadherin (d). Majority of NCI-H69V cells were negative for Zona Occludens,
but some single cells showed slight Zona Occludens expression (asterisk, e). Suspension cells (NCI-H69) are negative (c), whereas adherent NCI-H69V
are positive (f) for Vimentin (red). Ki-67 was co-stained (green). Cells were imaged by Zeiss Axioplan microscope and AxioCam Digital and analyzed by
ZeissAxioVision software. Bar represents 20 mm.
doi:10.1371/journal.pone.0100249.g001
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DNA methylation of Vimentin and E-cadherin
To assess whether epigenetic regulation by DNA promoter
methylation might play a role in expression levels, we applied
quantitative pyrosequencing to the promoter regions of Vimentin
and E-cadherin (Figure 3d). While the Vimentin promoter showed
DNA methylation levels of 35% in NCI-H69 cells, DNA
methylation levels in NCI-H69V cells were significantly lower
with 1,3% (p,0.0001). This leads to active gene transcription,
which falls in line with the observed increase in Vimentin on the
mRNA/protein level (Figure 1 and 2). Normal lung fibroblasts
(n = 3) showed Vimentin methylation levels of 1.1%. Conversely,
DNA methylation levels of E-cadherin/CDH1 were 31% in H69
cells and increased to 40% in NCI-H69V cells (p = 0.0032).
Normal lung fibroblasts (n = 2) showed 17% and 8% methylation,
respectively. This inverse correlation between expression and
DNA methylation may suggest that DNA methylation contributes
to Vimentin and E-cadherin mRNA regulation and protein
expression during the EMT process in SCLC cell lines.
Higher migration and invasive potential of adherent NCI-
H69
To investigate whether these dramatic phenotypic differences
have functional consequences, we carried out transwell migration
and invasion assays. The adherent NCI-H69V cells demonstrated
significantly higher migration and invasion into extracellular
matrix proteins towards 10% FCS-containing medium than the
NCI-H69 cells (Figure 4). NCI-H69 showed very little migration
potential and nearly no invasion. The migration level in NCI-H69
suspension cells was 15 cells per migration chamber (66/n = 3),
whereas NCI-H69V rose 11-fold with 196 cells per migration
chamber (681/n = 3) (p = 0.0001). The invasion level in H69 was
7 cells per migration chamber (63/n = 3), whereas NCI-H69V
was 16-fold higher with 118 cells per migration chamber (635/
n = 3) (p = 0.0001).
Live cell imaging of extracellular proteolytic activity
indicates higher proteolytic potential of adherent
sublines
Cancer cell invasion is accompanied by degradation of
Extracellular Matrix (ECM). Because of greater invasion of the
adherent subline, we analyzed its potential for collagen IV
degradation. After 48 h of incubation on matrigel containing
DQ-collagen IV, adherent NCI-H69V cells revealed significantly
higher pericellular degradation of collagen than NCI-H69 cells as
measured by green fluorescence. Quantification of proteolytically
active cells revealed that 77% of the NCI-H69V cells were
positive, whereas only 8% of the NCI-H69 suspension cells were
positive (Figure 5).
Adherent sublines show increased expression and
secretion of MMPs
MMPs are known to be associated with increased invasion and
metastasis in different cancer entities. To evaluate whether MMPs
are involved in SCLC invasion and increased proteolytic activity,
we analyzed MMP expression and secretion. Analysis of mRNA
expression by RT-PCR revealed strong upregulation of MMP-1,
MMP-2, MMP-9, MMP-13 and MMP-14 in the adherent NCI-
H69V cells and of MMP-1, MMP-2 and MMP-13 in adherent
Figure 2. Morphologic differences within SCLC cell lines. NCI-H69 SCLC cell lines are growing in floating clusters (a) with a small
subpopulation of adherently-growing cells that were selected by disposing floating cells over multiple passages (b) resembling the established
subline NCI-H69V (c). NCI-N592 and NCI-H82 in typical floating clusters (d, f) and selected adherent cells (e, g). Adherent subpopulations reveal a
spindle shape, filopodia and microtentacles. Cells were imaged by Zeiss Axioplan microscope and AxioCam Digital and analyzed by Zeiss LSM Image
Browser. Bar represents 200 mm.
doi:10.1371/journal.pone.0100249.g002
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NCI-N592 cells (Figure S2a). Moreover, secreted MMPs were
determined in cell-conditioned medium (CCM) by MMP antibody
arrays (Figure 6a). Consistent with the observed mRNA expression
levels, MMP-1, MMP-9 and MMP-13 were more abundant in the
CCM of NCI-H69V cells (Figure 6c). Furthermore, the amounts
of tissue inhibitors in metalloproteinases (TIMP-1, TIMP-2 and
TIMP-4) were elevated (Figure 6c). For MMP-2, we did a control
western blot that revealed MMP-2 being more secreted into the
CCM in NCI-H69V cells (Figure S2b). In addition, gelatin
zymography confirmed MMP-2 and MMP-9 activation. Indeed,
the bands characteristic for active MMP-2 and MMP-9 were
significantly enhanced in adherent NCI-H69V compared to
floating NCI-H69 cells (Figure 6d and e). Membrane-bound
MMP-14 is required to activate MMP-2 and is known to be
involved in cancer invasion. We observed a 2.2-fold change in
MMP-14 mRNA levels and a 13.8-fold change in MMP-14
protein levels in NCI-H69V compared to NCI-H69 suspension
cells (representative PCRs and western blots are shown in Figure
S2a,b). In summary, the adherent NCI-H69V subline demon-
strated increased expression and secretion of MMPs compared to
the parental NCI-H69.
Taken together, the migration, invasion, degradation of ECM
and MMP expression are in line with observed EMT marker
changes towards a mesenchymal-like subpopulation, represented
by NCI-H69V cells.
Figure 3. Expression and methylation of EMT and neuroendocrine markers in different SCLC cell lines. EMT markers and transcription
factors are expressed differently within the SCLC lines (NCI-H69, NCI-H82, and NCI-N592). NCI-H69 cells did not express mesenchymal markers or
inductors in suspension cultures, evident on the mRNA level by RT-PCR (a). Zeb1, Snail/Snai1, Slug/Snai2, and FSP are expressed in the adherent
subline (NCI-H69V), but E-cadherin is only expressed in suspension cells. Mesenchymal markers Fibronectin and Vimentin are upregulated in the
adherent sublines (a). The mRNA expression in NCI-H82 and NCI-N592 compared with its adherent subcultures generally revealed a similar tendency
toward a mesenchymal phenotype in the adherent cells (a). Western blot analysis displays decreased protein levels in the epithelial markers E-
cadherin and Zona occludens 1, and expression of mesenchymal markers Vimentin and ZEB1 in NCI-H69V. EMT inductors Snail/Snai1, Slug/Snai2 are
expressed in NCI-H69V (b). The expression change in adherent NCI-N592 toward a mesenchymal-like phenotype is more significant on the protein
level than the mRNA level (b). The neuroendocrine markers NSE and L-Dopa are expressed in the parental cell line NCI-H69, but are not detectable in
the adherent subline NCI-H69V (c). DNA methylation analysis (d) of the EMT hallmark gene Vimentin demonstrates strong methylation in NCI-H69
and significant hypomethylation in NCI-H69V, E-cadherin methylation is significantly higher in H69V. As control, cultured lung fibroblasts isolated
from three patients for Vimentin methylation levels and from two patients for E-cadherin methylation levels without fibrotic diseases served as
normal control. The bar shows the mean of three independent measurements. The differences between the mean methylation levels of the analyzed
amplicon was tested using Student’s unpaired t-test (* p value from 0.01 to 0.05, ** p value from 0.01 to 0.001 and *** p value less than 0.001).
doi:10.1371/journal.pone.0100249.g003
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Figure 4. Increased migration and invasion in adherent NCI-H69V sublines. Adherently-growing NCI-H69 cells demonstrate significantly
higher migration (a) and invasion (b) towards 10% FCS containing medium compared to the suspension cell line (*** p = .0001). Migration Index was
defined as number of migrated cells divided by number of migrated cells in the untreated group (no FCS) after 48 hours. Invasion Index was defined
as number of counted cells in five view fields divided by the number of migrated cells in the untreated group (no FCS) after 48 hours.
doi:10.1371/journal.pone.0100249.g004
Figure 5. Extracellular proteolytic activity comparing NCI-H69 and NCI-H69V sublines. Live-cell proteolysis assay: suspension NCI-H69 and
adherent NCI-H69V cells were incubated for 48 hours on matrigel containing 30 ng/ml DQ-collagen IV. (a) Degradation of collagen is determined by
green fluorescence that surrounds positive cells. Bar represents 30 mm. (b) Diagram shows mean values of three independent experiments with
standard deviation.
doi:10.1371/journal.pone.0100249.g005
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Increased drug resistance of adherent NCI-H69V cells
Another feature many tumors acquire during EMT is drug
resistance. We analyzed resistance to Etoposide, a standard
chemotherapeutic drug in SCLC therapy. NCI-H69 and NCI-
H69V cells were treated with 200 mM Etoposide for 48 h before
testing cell viability via DIOC6/PI staining (Figure 7a: NCI-H69,
7b: NCI-H69V). Cell viability fell to 29% (65,66%) after 48 h
treatment compared to 66% (68,49%) in the untreated NCI-H69
suspension. Cell viability in the adherent NCI-H69V remained at
81% (66,36%) compared to 88% (62%) in untreated cells after
48 h treatment (Figures 7c–d), indicating that the adherent subline
is more drug-resistant than NCI-H69 suspension cells (Figure 7),
thus proving drug resistance as one characteristic of EMT [22].
Discussion
Primary tumors and metastases are often composed of
heterogeneous cell populations containing differentiated and
dedifferentiated cells, particularly located at the invasive front.
The latter cells are described as displaying those hallmarks of
EMT associated with increased tumor-cell dissemination [19].
SCLC cell lines in culture always reveal cell heterogeneity, with
a majority of cells growing in floating cell aggregates
(Figures 2a,d,f) and a smaller fraction of adherently growing cells
(Figures 2b,c,e,g). The percentage of adherent cells depends on
factors such as hypoxia, malnutrition, cell density and other stress
factors [20].
In our study we examined the composition of SCLC cell lines
and their adherent sublines with regard to EMT markers. As the
cell lines differed significantly in expressing epithelial markers such
as E-cadherin and Zona Occludens and mesenchymal markers like
Vimentin (Figure 1), we hypothesized that these sublines might
display tumor-cell heterogeneity occurring in vivo. We are aware
that this is an artificial in vitro cell line model and in vivo
heterogeneity is never restricted to these two extremes with clear
cut epithelial and mesenchymal characteristics. Nevertheless, these
cell sublines might be a useful tool to study phenotypical and
functional differences.
There is evidence that EMT processes, including the ability of
cells to invade and migrate into surrounding tissues, are
accompanied by changes in cell morphology [13,14], yet very
little is known about EMT processes in SCLC. Nevertheless, it
could be essential to understanding the unique clinical behavior of
SCLC compared to other lung cancer entities. The spindle-shaped
appearance, formation of microtentacles and loss of basal-apical
polarity were observed in the adherent SCLC cell sublines (NCI-
H69V, and the adherent sublines of NCI-H69, NCI-N592, and
NCI-H82) with mesenchymal characteristics (Figure 1, 2). In
contrast, the floating cell aggregates in the cell lines (NCI-H69,
NCI-N592) showed characteristics of epithelial-like cells (Figures 1,
2).
Further analyses of EMT-marker expression at mRNA and
protein levels in the adherent sublines revealed that typical
epithelial markers like Zona occludens 1 and E-cadherin were
downregulated, whereas Vimentin as a typical mesenchymal
marker was upregulated (Figures 3a, b). In contrast, the floating
and tightly-packed cells demonstrated high E-cadherin and Zona
occludens 1 expression. Changes from E-cadherin expression
towards Vimentin expression is a hallmark characteristic of EMT
[23,24]. The transmembrane glycoprotein E-cadherin is charac-
teristic of epithelial cells. It functions in maintaining regular
epithelial tissue structure by mediating cell polarity through
interaction with the actin cytoskeleton [25]. Vimentin is an
intermediate filament and hence a component of the cytoskeleton
found in mammalian cells and expressed ubiquitously in mesen-
chymal cells [25]. The overexpression of Vimentin in cancers is
known to correlate with accelerated tumor growth, invasion, and
poor prognosis [26].
E-cadherin repression and Vimentin upregulation are regulated
by the transcription factors Snail/Snai1, Slug/Snai2, Zeb1 [27].
Figure 6. Secretion and activation of MMPs by NCI-H69 and NCI-H69V sublines. Secreted MMPs were analyzed in NCI-H69 suspension and
NCI-H69V cells by antibody arrays (a). Mapping of spots (b), antibody arrays were then quantified by ImageJ. The bars represent means of two
independent experiments (c), white bar: NCI-H69/gray bar: NCI-H69V/black bar: medium control. Activation of MMP-2 and MMP-9 were determined
by gelatin zymography (d) and quantified by ImageJ (e). The diagram shows mean values of three independent experiments with standard deviation
(e).
doi:10.1371/journal.pone.0100249.g006
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These transcription factors were upregulated in the adherent,
mesenchymal-like subpopulation of NCI-H69V cells compared to
parental suspension cultures (Figures 3a,b). We observed this in the
other cell lines to a lesser extent, perhaps because NCI-H82 and
NCI-N592 already contain a higher proportion of adherent cells,
meaning that the separation between more epithelial-like and
mesenchymal-like cells was not as obvious as in the NCI-H69/
NCI-H69V cells. This might also explain the expression of
Vimentin in NCI-H82 suspension cells. However, Vimentin
expression remains clearly increased in the adherent NCI-H82
subline. Despite small discrepancies among the three cell lines we
analyzed, our overall data clearly indicate a more mesenchymal
phenotype for the adherent SCLC cells. We suggest that multistep
EMT processes are involved in these complex changes in
phenotypes in all three cell lines, which is also supported by the
epigenetic and functional changes outlined below.
Interestingly, the neuroendocrine marker expression of SCLC
cells is also significantly different in adherent NCI-H69V cells
compared to suspension NCI-H69 cells. Expression of NSE and L-
Dopa is completely lost in adherent NCI-H69V cells (Figure 3c).
We know that neuroendocrine and non-neuroendocrine subpop-
ulations coexist in some tumors [28]. Changes in morphology are
accompanied by the loss of neuroendocrine differentiation and the
emergence of radio resistance [29] while Vimentin positive cells
are losing their apical-basal polarity and neuroendocrine differ-
entiation [30]. Our data concur with these earlier observations,
indicating that neuroendocrine differentiation is lost during EMT
of SCLC cells.
The rise in Vimentin expression has been reported to be
associated with tumor migration, invasion and metastasis [31].
Polarized cell movement and matrix degradation is typical in
mesenchymal migration and invasion [32]. In contrast, E-cadherin
is typically expressed on epithelial cell layers that do not form
metastases [33]. To form metastases, cells detach from neighbor-
ing cells, leave the tumor site, and invade blood and lymphatic
vessels before settlement at the metastatic site [34]. Concurring
with these descriptions of functions gained during EMT that are
also linked to stemness properties [18,35], we also observed
significantly increased migratory und invasive potential in the
adherent, mesenchymal-like NCI-H69V cells (Figure 4).
Furthermore, we detected a significant increase in extracellular
proteolysis of collagen IV in NCI-H69V cells, whereas NCI-H69
cells growing in suspension aggregates revealed low proteolytic
activity (Figure 5). This lack of proteolytic activity corresponds
with their non-invasive behavior (Figure 4), as ECM degradation is
a prerequisite for invasion into surrounding tissue. Matrix
remodeling is mainly mediated by MMPs; a correlation between
mesenchymal characteristics and higher MMP expression has
been reported [36]. MMPs, especially MMP-2 and MMP-9, as
well as their endogenous inhibitors (TIMPs, especially TIMP1) are
known to be important in tumor development [37,38], tumor cell
invasion and metastasis. Their expression correlates with advanced
clinical tumor disease stages and poor survival [39,40]. We
observed increased MMP-9, MMP-13, TIMP-1 and TIMP-2
expression and increased MMP-9 and MMP-2 activity (Figure 6).
MMP-2 interacts with integrins and results in locally-enhanced
matrix degradation [41] and elevated MMP-2 and MMP-9
expression is associated with tumor aggressiveness and invasion
[42]. Thus we suggest that enhanced secretion and activation of
distinct MMPs such as MMP-2, MMP-9 and MMP-13 are at least
partially responsible for the greater invasive capacity of the
adherent subpopulation.
Unlike the other MMPs, MMP-10 was decreased in adherent
NCI-H69V cells compared to floating NCI-H69. In agreement
with our findings, Justilien et al. reported increased expression of
Figure 7. Higher chemoresistance of H69V cells compared to NCI-H69. NCI-H69V treated with 200 mM Etoposide showed significantly
increased chemoresistance in comparison to NCI-H69 cells. After 48 h treatment with Etoposide, cells were stained with Propidium iodide and DiOC6
to detect vital, dead and apoptotic cells via flow cytometry. Dot plots of one representative experiment repeated three times (a, b). Mean values from
the three independent experiments of vital, dead and apoptotic cells are displayed as percentage of untreated controls (c). Cell viability of NCI-H69
and NCI-H69V after Etoposide treatment expressed as mean values and standard error of three independent experiments (d).
doi:10.1371/journal.pone.0100249.g007
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MMP-10 in oncospheres and a loss of MMP-10 expression in
adherent cultures [43].
Besides its important role in metastasis, EMT is also known to
be associated with the development of chemoresistance and early
relapse in several cancer types [15]. We noted a significant
increase in Etoposide resistance in the adherent, mesenchymal-like
NCI-H69V cells compared to the NCI-H69 cells floating in
aggregates (Figure 7). NCI-H69 and NCI-H69V cells showed
comparable PDTs (Figure S1) so that chemoresistance is unlikely
to be caused by a growth advantage of NCI-H69V over NCI-H69.
Comparable PDTs were described before for NCI-H69 and a
multidrug resistant subline, which also showed enhanced cell-cell
adhesiveness [44]. Moreover, similar results on chemoresistance
comparing suspension and adherent sublines were previously
obtained by Kraus et al. [45] for Etoposide and to a lesser extent
also for Cyclophosphamide, Doxorubicin and Paclitaxel. During
treatment of patients suffering from SCLC, physicians encounter a
very good initial response to chemotherapy, invariably followed by
a relapse resulting in terrible five-year survival rates. Such relapses
might originate from a minor SCLC subpopulation with EMT
abilities. Further investigations on primary SCLC cells are needed
to address the question whether the differences observed in our
experiments regarding EMT-like features reflect the clinical
situation.
In an effort to understand the underlying mechanism of these
morphological and functional changes, we investigated the impact
of epigenetic changes via DNA methylation in NCI-H69V
compared to NCI-H69 cells. Epigenetic changes are involved in
regulating EMT and cancer metastasis [15]. Moreover, epigenetic
modifications are known to result in activating oncogenic
pathways while inactivating tumor-suppressor signals [46]. There
are reports that E-cadherin and Vimentin can be regulated via
DNA methylation in various cancer entities [47,48]. We therefore
investigated DNA methylation levels of the Vimentin and E-
cadherin promoter and found a strong inverse correlation between
DNA methylation and expression in NCI-H69 and NCI-H69V
cells, especially for Vimentin (Figure 3d). While other regulatory
mechanisms are probably involved as well, our data demonstrate
the contribution of DNA methylation in modulating the expres-
sion of key EMT-related proteins.
The investigation of SCLC is hampered by the fact that primary
tumor tissue is very difficult to obtain because SCLC patients do
not usually undergo surgery. In this respect, the characterization of
different tumor-cell subpopulations within SCLC cell lines might
at least partially reflect the in vivo situation with its shifting
phenotypes that might recapitulate the clinical observation of high
initial chemotherapy responses and refractory disease in relapse.
We propose that this model deserves further examination, and that
ongoing in vivo xenograft studies will help us address this disease’s
clinical and therapeutic relevance. As EMT processes seem to play
a major role in metastasis and the development of drug resistance,
understanding the regulating factors of EMT in SCLC is crucial to
developing new therapeutic strategies.
In conclusion, we have characterized the floating and adherent
subpopulations of different SCLC cell lines in vitro in terms of their
epithelial and mesenchymal markers and their functional conse-
quences in migration, invasion, MMP regulation and chemoresis-
tance. This new in vitro cell model might prove to be a useful tool in
identifying specific targets for distinct subpopulations with
mesenchymal-like features such as the greater capacity to
metastasize and develop drug resistance. Moreover, our study
demonstrates the involvement of DNA methylation in this process,
making epigenetic drugs such as the DNA-methyltransferase-
inhibitors Azacytidine or Decitabine interesting candidates for new
treatment options for patients with chemotherapy-resistent SCLC.
The clinical relevance of EMT and epigenetic aberrations in
SCLC patients demands further investigation to clearly define new
targeted therapies.
Supporting Information
Figure S1 Cell growth and population doubling time
(PDT) of NCI-H69 and NCI-H69V. Means of triplicates are
shown. 3*106 cells were seeded at day 0 and counted on day 2, 4,
and 6. Similar results were obtained in several experiments.
(DOC)
Figure S2 Analysis of MMP mRNA and protein levels in
suspension cells and their adherent sublines. Majority of
analyzed MMPs, especially MMP-2, MMP-9 and MMP-14, are
up-regulated in adherently growing NCI-H69V and NCI-
N592adh compared to their floating counterparts NCI-H69 and
NCI-N592, as shown by RT-PCR (a). Only MMP-10 was slightly
down-regulated in NCI-H69V cells. Upregulation on protein level
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